Two IDH-inhibitors, enasidenib (IDHIFA, AG-221) for mIDH2 and ivosidenib (TIBSOSOV, AG-120) for mIDH1 were recently approved by the FDA for r/r AML based on two single arm studies [36,37]. This evidence concerns the gene IDH1 and acute myeloid leukemia.